Evoke Pharma Secures New GIMOTI Patent Enhancing Market Position
Evoke Pharma Secures New GIMOTI Patent Enhancing Market Position
Evoke Pharma, Inc. (NASDAQ: EVOK) has made a significant advancement in its portfolio by listing U.S. Patent No. 12,377,064 for GIMOTI (metoclopramide) nasal spray in the FDA's Orange Book, a crucial milestone for the specialty pharmaceutical company. This patent covers the application of GIMOTI in treating moderate to severe symptoms of gastroparesis.
CEO Matt D'Onofrio remarked, "This patent exemplifies our dedication to innovating treatment options for patients while safeguarding our investments in the development of novel drugs." The patent boasts an expiration date in November 2038, extending the commercial viability of GIMOTI significantly beyond the previous patent expiration of May 2030.
Evoke Pharma's long-term strategy emphasizes maximizing GIMOTI's market presence and ensuring consistent access for patients who rely on non-oral delivery systems for effective diabetic gastroparesis treatment. By doing so, Evoke reaffirms its commitment to advancing healthcare solutions for complex medical conditions.
Understanding Diabetic Gastroparesis and GIMOTI's Role
Diabetic gastroparesis is a debilitating condition affecting countless individuals, where the stomach's ability to empty is severely delayed, leading to uncomfortable symptoms and complications. GIMOTI, a unique nasal spray formulation of metoclopramide, stands out as the only FDA-approved medication for this condition in the U.S., which previously was only available in oral and injectable forms.
By providing a non-oral option, GIMOTI offers a vital solution for patients whose stomachs are unable to effectively process orally administered medications, allowing for improved management of their condition.
About Evoke Pharma's Innovations
Evoke Pharma is devoted to developing specialized drugs aimed at treating gastrointestinal (GI) disorders. The company's leading product, GIMOTI, is designed to alleviate symptoms in adults suffering from acute and recurrent diabetic gastroparesis. This focus on a niche area within the pharmaceutical field enables Evoke to play a pivotal role in enhancing patient care.
GIMOTI's Key Benefits and Safety Information
GIMOTI is specifically indicated for adults dealing with symptoms of diabetes-related gastroparesis. However, it is crucial to be aware of potential side effects associated with metoclopramide. One serious concern is tardive dyskinesia (TD), a long-lasting movement disorder that may occur, worsening with prolonged treatment. It's essential to monitor any symptoms relevant to TD and discontinue use if they arise.
Moreover, GIMOTI isn't suitable for pediatric patients and those with certain liver and kidney issues. Careful attention should also be given to patients on specific medications that might interact unfavorably with metoclopramide.
Enhancing Patient Awareness
As part of their mission, Evoke Pharma is committed to ensuring that healthcare providers and patients are well-informed about GIMOTI and its benefits. They encourage consultation with healthcare professionals to discuss risks, benefits, and any concerns regarding suitable treatments for diabetic gastroparesis.
How to Stay Updated with Evoke Pharma
Evoke invites stakeholders and interested parties to stay connected via their official website, where further developments and news will be announced regularly. Additionally, for immediate updates, follow their social media platforms, including LinkedIn and Twitter, where the company shares insights and information about their products and initiatives.
Frequently Asked Questions
What is GIMOTI used for?
GIMOTI is primarily used to relieve symptoms in adults with diabetic gastroparesis, a condition where the stomach takes too long to empty.
How long does the GIMOTI patent last?
The listed patent for GIMOTI is set to expire in November 2038, extending its market exclusivity significantly.
Are there any serious side effects associated with GIMOTI?
Yes, one serious side effect of metoclopramide, the active ingredient in GIMOTI, is tardive dyskinesia, which can be irreversible in some cases.
What distinguishes GIMOTI from other metoclopramide formulations?
GIMOTI is unique as it provides a nasal spray option, which is beneficial for patients who cannot take oral medications effectively due to gastrointestinal complications.
How can I learn more about Evoke Pharma and its products?
You can visit Evoke Pharma’s official website or follow them on social media platforms for the latest news and updates regarding their products and initiatives.
About The Author
Contact Logan Wright privately here. Or send an email with ATTN: Logan Wright as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.